SRPT:NGS-Sarepta Therapeutics Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 119.26

Change

+0.53 (+0.45)%

Market Cap

USD 1.99B

Volume

0.65M

Analyst Target

USD 195.05
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.07 (-0.27%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+7.05 (+0.79%)

USD 106.98B
MRNA Moderna Inc

-0.35 (-0.34%)

USD 39.68B
ARGX argenx NV ADR

-4.48 (-1.21%)

USD 22.63B
BNTX BioNTech SE

+0.06 (+0.07%)

USD 21.93B
GMAB Genmab AS

-0.90 (-3.06%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-1.40 (-0.95%)

USD 18.55B
RPRX Royalty Pharma Plc

+0.15 (+0.55%)

USD 18.18B
BGNE BeiGene Ltd

-2.19 (-1.63%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-0.40 (-0.44%)

USD 16.06B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 8.88 % 0.00 %

-0.06 (-1.69%)

USD 0.13B
MSGR 6.12 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 5.29 % 0.00 %

-1.01 (-1.69%)

CAD 5.07M
IBRN iShares Trust - iShares N.. 5.04 % 0.00 %

-0.23 (-1.69%)

USD 3.86M
CURE:XETRA VanEck Genomics and Healt.. 4.07 % 0.00 %

-0.08 (-1.69%)

USD 6.89M
GNOG:LSE Global X Genomics & Biote.. 3.92 % 0.00 %

-0.09 (-1.69%)

USD 8.88M
BIOT:SW L&G Pharma Breakthrough U.. 3.61 % 0.00 %

-0.15 (-1.69%)

N/A
LSEQ Harbor Long-Short Equity .. 2.44 % 0.00 %

-0.45 (-1.69%)

USD 0.01B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.45 % 0.00 %

-6.95 (-1.69%)

USD 0.02B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.43 % 0.00 %

-0.09 (-1.69%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.41 % 0.00 %

-0.07 (-1.69%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.41 % 0.00 %

-0.07 (-1.69%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.41 % 0.00 %

-0.06 (-1.69%)

N/A
CURE:AU ETFS S&P Biotech ETF 1.06 % 0.00 %

-0.09 (-1.69%)

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

-0.59 (-1.69%)

USD 0.02B
JKJ iShares Morningstar Small.. 0.00 % 0.25 %

N/A

USD 0.22B
JKK iShares Morningstar Small.. 0.00 % 0.30 %

N/A

USD 0.54B
LABS 0.00 % 0.45 %

N/A

N/A
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.39 (-1.69%)

USD 0.04B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.11 (-1.69%)

USD 0.10B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.08 (-1.69%)

USD 0.02B
DWEQ 0.00 % 0.00 %

N/A

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

-0.43 (-1.69%)

USD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.28% 39% F 63% D
Dividend Return N/A N/A N/A N/A F
Total Return 9.28% 39% F 63% D
Trailing 12 Months  
Capital Gain 98.27% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 98.27% 94% A 97% N/A
Trailing 5 Years  
Capital Gain 325.93% 92% A 97% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 325.93% 92% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 67.92% 90% A- 96% N/A
Dividend Return 67.92% 90% A- 96% N/A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 85.54% 21% F 7% C-
Risk Adjusted Return 79.40% 96% N/A 78% C+
Market Capitalization 1.99B 97% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -31.72 95% 91%
Price/Book Ratio 11.38 10% 8%
Price / Cash Flow Ratio -6.52 91% 93%
Price/Free Cash Flow Ratio -22.85 88% 89%
Management Effectiveness  
Return on Equity -33.74% 68% 25%
Return on Invested Capital -19.94% 79% 31%
Return on Assets -19.45% 80% 26%
Debt to Equity Ratio 59.50% 22% 42%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.